Skip to main content

01-01-2015 | Osteoarthritis | Book Chapter | Article

9. Osteoarthritis Biomarkers

Authors: PhD Ying-Hua Li, MD, MSc Christopher Kim, MD, MSc Rajiv Gandhi

Publisher: Springer International Publishing


  • Biomarkers in OA can be categorized using the BIPEDS classification: burden of disease, investigative, prognostic, efficacy of intervention, diagnostic, and safety.
  • Urine CTX-II and serum COMP seemed to have the best performance and promise of all commercially available OA biomarkers.
  • Identification and validation of panels of biomarkers correlated with imaging modalities may provide improved diagnosis, prediction, and understanding of the pathogenesis of OA.
  • Catabolic factors reflecting the degradation of cartilage joint tissue remain the most promising OA biomarkers and are awaiting validation in clinical trials.
  • Omics-based technology platforms, including DNA microarray, transcriptomics, proteomics, and metabolomics, are being increasingly applied in OA research and have identified significant amount of new potential OA biomarkers.
  • Aberrantly expressed miRNAs contribute to the pathogenesis of OA and could serve as potential therapeutic targets to treat OA, as well as diagnostic biomarkers.
  • Circulating miRNAs have emerged as a new class of minimally or noninvasive OA biomarkers due to their highly stability and ease of detection.

Please log in to get access to this content

Related topics